|
Pipeline to Partnerships (P2P)
|
Title
|
Company Name
|
Platform /
Modality
|
Target
|
Investor/Partner
Relations
|
| Active Dry Powder Inhaler |
Oriel Therapeutics Inc |
Other (Device for delivering therapeutics to the lung) |
|
Strategic Partner |
| Novel Technology for cost-effective production of improved antibodies |
ApoLife, Inc. |
Antibody |
CLL and breast cancer |
VC, Licensing, Manufacturing, Strategic Partner |
| A New Class of Pan-HER Antagonists to Treat Cancer |
Molecular LogiX |
Biologic |
HER family of receptor tyrosine kinases |
VC, Strategic Partner |
| A Novel Holographic Detector for Remote Sensing of Environmental Hazards |
AlphaSniffer, LLC |
Point of Care |
infectious disease agents, including biological warfare agents, for clinical application and also infrastructure and personnel protection |
VC, Licensing, Strategic Partner, Other |
| Oral Clinical Drug for Asthma & COPD |
Inverseon, Inc. |
Small Molecules |
Inflammatory Pathway |
VC, Licensing, Manufacturing, Strategic Partner |
| Technology and Device for Asthma Treatment |
General Innovations &Goods, Inc. |
Other (Device for asthma and infections control) |
Reduces airborne allergens and infections agents -The airway inflammation and reactivity associated with asthma will be reduced by lowering the level of exposure to extrinsic factors associated with asthma and by exposing the patient to deactivated airborne allergens. |
VC, Licensing |
|
represents column sort